The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Open accessAbstract
Patients with Fabry disease (FD) are at a high risk for developing chronic kidney disease and cardiovascular disease. The availability of specific but costly therapy has elevated the profile of this rare condition. This KDIGO conference addressed controversial areas in the diagnosis, screening, and management of FD, and included enzyme replacement therapy and nonspecific standard-of-care therapy for the various manifestations of FD. Despite marked advances in patient care and improved overall outlook, there is a need to better understand the pathogenesis of this glycosphingolipidosis and to determine the appropriate age to initiate therapy in all types of patients. The need to develop more effective specific therapies was also emphasized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178233 · Cited by 1,080
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Treatment of neuropathic pain: an overview of recent guidelines.
O'Connor, A. B., & Dworkin, R. H. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.04.007 · Cited by 781
Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., & Levey, A. S. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006101081 · Cited by 162
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Lenders, M., Stypmann, J., Duning, T., Schmitz, B., Brand, S.-M., & Brand, E. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121226 · Cited by 133
Cited by
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Self-citationFabry disease revisited: Management and treatment recommendations for adult patients
Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., et al. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.02.014 · Cited by 650
Self-citationDeRosa, F., Smith, L., Shen, Y., Huang, Y., Pan, J., Xie, H., Yahalom, B., & Heartlein, M. W. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.001 · Cited by 111
Current and Investigational Therapeutics for Fabry Disease
Felis, A., Whitlow, M., Kraus, A., Warnock, D. G., & Wallace, E. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2019.11.013 · Cited by 100
Self-citation
Metadata
- Authors
- Schiffmann, R., Hughes, D. A., Linthorst, G. E., Ortiz, A., Svarstad, E., Warnock, D. G., West, M. L., Wanner, C., Bichet, D. G., Christensen, E. I., Correa-Rotter, R., Elliott, P. M., Feriozzi, S., Fogo, A. B., Germain, D. P., Hollak, C. E. M., Hopkin, R. J., Johnson, J., Kantola, I., Kopp, J. B., Kröner, J., Linhart, A., Martins, A. M., Matern, D., Mehta, A. B., Mignani, R., Najafian, B., Narita, I., Nicholls, K., Obrador, G. T., Oliveira, J. P., Pisani, A., Politei, J., Ramaswami, U., Ries, M., Terryn, W., Tøndel, C., Torra, R., Vujkovac, B., Waldek, S., & Walter, J.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 91
- Issue
- 2
- Pages
- 284-293
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2562426643
- Cited by
- 194
- References
- 8
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.